MEI Pharma Appoints Industry Veteran Frederick W. Driscoll to its Board of Directors

MEI Pharma Appoints Industry Veteran Frederick W. Driscoll to its Board of Directors

SAN DIEGO, February 26, 2018 MEI Pharma, Inc. (NASDAQ: MEIP), an oncology company focused on the clinical development of novel therapies for

cancer, today announced the appointment of Frederick W. Driscoll to its board of directors. Mr. Driscoll will serve on the audit committee.

As an industry veteran, Fred brings MEI a tremendous amount of industry and financial experience that we can leverage to effectively advance our

oncology pipeline as our programs move into later stage development, said Daniel P. Gold, Ph.D., president and chief executive officer of MEI Pharma. We look forward to working with Fred and adding his valuable contributions to our

Mr. Driscoll currently serves on the board of directors of Abpro Therapeutics, Cellectar Biosciences, Inc. (NASDAQ: CLRB) and

NantKwest, Inc. (NASDAQ: NK) He served as the chief financial officer of Flexion Therapeutics, Inc. (NASDAQ: FLXN) from 2013 to 2017 and before joining Flexion, he was the chief financial officer at Novavax, Inc. from 2009 to 2013. From 2008 to

2009, Mr. Driscoll served as the chief executive officer at Genelabs Technologies, Inc. and from 2007 to 2008 he served as the company s chief financial officer. He was also the chief executive officer of OXiGENE, Inc. from 2000 to 2006.

Mr. Driscoll also served as the chairman of the board and audit committee chair at OXiGENE and as a member of the audit committee for Cynapsus Therapeutics, Inc. Mr. Driscoll earned a bachelor s degree in accounting and finance from

Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company s portfolio of drug candidates includes pracinostat, an oral HDAC inhibitor that is partnered with Helsinn

Healthcare, SA. Pracinostat has been granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for use in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are

unfit for intensive chemotherapy. Pracinostat is also being developed in combination with azacitidine for the treatment of patients with high and very high-risk myelodysplastic syndrome (MDS) (NCT03151304). MEI Pharma s clinical development

pipeline also includes ME-401, a highly differentiated oral PI3K delta inhibitor currently in a Phase 1b study in patients with relapsed/refractory CLL or follicular lymphoma, and voruciclib, an oral,

selective CDK inhibitor shown to suppress MCL1, a known mechanism of resistance to BCL2 inhibitors. The Company is also developing ME-344, a novel mitochondrial inhibitor currently in an investigator-sponsored

study in combination with bevacizumab for the treatment of HER2-negative breast cancer. Pracinostat, ME-401, ME-344 and voruciclib are investigational agents and are not

approved for use in the U.S. For more information, please visit www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has

been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are forward-looking statements within the meaning

of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on

management s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully

commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in

interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing,

sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate

our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes;

government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking

VP of IR and Corporate Communications

Canale Communications for MEI